当前位置: X-MOL 学术Bipolar Disord. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder
Bipolar Disorders ( IF 5.0 ) Pub Date : 2020-12-25 , DOI: 10.1111/bdi.13041
Ateeq Ahmad 1 , Saifuddin Sheikh 1 , Mujtaba Ali Khan 2 , Alok Chaturvedi 2 , Piyush Patel 2 , Ronak Patel 3 , Bakul Chandrakant Buch 4 , Rajendra Someshwar Anand 5 , Timirkumar Chandrakant Shah 6 , Vaishal Nareshchandra Vora 7 , Vikhram Ramasubramanian 8 , Satyanarayana Rao 9 , Narendra Kumar 10 , B S V Prasad 11 , Ramanathan Sathianathan 12 , Kamal Kumar Verma 13 , Venu Gopal Jhanwar 14 , Nand Kumar 15 , Sandip Shah 16 , Pronob Kumar Dalal 17 , Brahmdeep Sindhu 18 , Payel Talukdar 19 , Imran Ahmad 1
Affiliation  

Endoxifen is a protein kinase C inhibitor. The objective of the present phase III study was to demonstrate the safety and efficacy of endoxifen in treating bipolar I disorder (BPD I) patients.

中文翻译:

Endoxifen:一种新的蛋白激酶 C 抑制剂,用于治疗与 I 型双相情感障碍相关的急性和混合性躁狂症

Endoxifen 是一种蛋白激酶 C 抑制剂。本 III 期研究的目的是证明 endoxifen 治疗双相 I 型障碍 (BPD I) 患者的安全性和有效性。
更新日期:2020-12-25
down
wechat
bug